Bristol Myers Squibb Files 8-K on Financial and Corporate Matters

Ticker: CELG-RI · Form: 8-K · Filed: Jan 13, 2025 · CIK: 14272

Bristol Myers Squibb Co 8-K Filing Summary
FieldDetail
CompanyBristol Myers Squibb Co (CELG-RI)
Form Type8-K
Filed DateJan 13, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.10
Sentimentneutral

Sentiment: neutral

Topics: debt-issuance, corporate-filing, financial-disclosure

Related Tickers: BMY

TL;DR

BMS filed an 8-K detailing debt notes and Celgene CVRs.

AI Summary

Bristol Myers Squibb Company filed an 8-K on January 13, 2025, reporting on various financial and corporate events. The filing includes information related to their common stock, specific debt issuances such as the "One 750 Notes Due 2035" and "One 000 Notes Due 2025", and contingent value rights associated with Celgene. The company is incorporated in Delaware and headquartered in Princeton, New Jersey.

Why It Matters

This 8-K filing provides crucial updates on Bristol Myers Squibb's financial instruments and corporate structure, which can impact investors' understanding of the company's debt obligations and equity.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of corporate and financial information, not indicating any immediate operational or financial distress.

Key Numbers

  • 001-01136 — SEC File Number (Identifier for Bristol Myers Squibb's SEC filings)
  • 22-0790350 — IRS Employer Identification No. (Tax identification number for the company)

Key Players & Entities

  • Bristol Myers Squibb Company (company) — Registrant
  • Delaware (jurisdiction) — State of incorporation
  • Princeton, New Jersey (location) — Principal executive offices
  • One 750 Notes Due 2035 (financial_instrument) — Debt issuance
  • One 000 Notes Due 2025 (financial_instrument) — Debt issuance
  • Celgene Contingent Value Rights (financial_instrument) — Contingent value rights

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on significant corporate events and financial matters, including details on debt issuances and contingent value rights.

When was this 8-K filing submitted?

This 8-K filing was submitted on January 13, 2025.

What specific debt instruments are mentioned in the filing?

The filing mentions "One 750 Notes Due 2035" and "One 000 Notes Due 2025".

What is the company's state of incorporation?

Bristol Myers Squibb Company is incorporated in Delaware.

What is the address of the company's principal executive offices?

The principal executive offices are located at Route 206 & Province Line Road, Princeton, New Jersey 08543.

Filing Stats: 581 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-13 10:20:34

Key Financial Figures

  • $0.10 — nge on which registered Common Stock, $0.10 Par Value BMY New York Stock Exchan

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On January 13, 2025, Bristol-Myers Squibb Company (the "Company") posted an investor presentation to its website at: www.bms.com/investors/events-and-presentations.html. A copy of the investor presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise be subject to the liabilities thereof, nor shall it be incorporated by reference into any filing by the Company under the Exchange Act or under the Securities Act of 1933, as amended, whether made before or after the date hereof regardless of any general incorporation language in such filing. The furnishing of this information hereby shall not be deemed an admission as to the materiality of any such information.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished as part of this Current Report on Form 8-K: Exhibit No. Description 99.1 Investor presentation of Bristol-Myers Squibb Company dated January 13, 2025. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRISTOL-MYERS SQUIBB COMPANY Dated: January 13, 2025 By: /s/ Amy Fallone Name: Amy Fallone Title: Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.